108 related articles for article (PubMed ID: 12680233)
21. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
22. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
Lotan Y; Gupta A; Shariat SF; Palapattu GS; Vazina A; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Perotte P; Schoenberg MP; Lerner SP; Sagalowsky AI
J Clin Oncol; 2005 Sep; 23(27):6533-9. PubMed ID: 16116151
[TBL] [Abstract][Full Text] [Related]
23. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
[TBL] [Abstract][Full Text] [Related]
24. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples.
Tsui KH; Juang HH; Lee TH; Chang PL; Chen CL; Yung BY
Acta Pharmacol Sin; 2008 Mar; 29(3):364-70. PubMed ID: 18298902
[TBL] [Abstract][Full Text] [Related]
25. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
26. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
27. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers.
Younes M; Lechago LV; Somoano JR; Mosharaf M; Lechago J
Cancer Res; 1996 Mar; 56(5):1164-7. PubMed ID: 8640778
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy.
Harada K; Sakai I; Hara I; Eto H; Miyake H
Int J Urol; 2005 Mar; 12(3):250-5. PubMed ID: 15828951
[TBL] [Abstract][Full Text] [Related]
29. Fatty acid synthase expression in squamous cell carcinoma of the tongue: clinicopathological findings.
Silva SD; Perez DE; Nishimoto IN; Alves FA; Pinto CA; Kowalski LP; Graner E
Oral Dis; 2008 May; 14(4):376-82. PubMed ID: 18410580
[TBL] [Abstract][Full Text] [Related]
30. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
31. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
[TBL] [Abstract][Full Text] [Related]
32. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
[TBL] [Abstract][Full Text] [Related]
33. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma.
Sebastiani V; Visca P; Botti C; Santeusanio G; Galati GM; Piccini V; Capezzone de Joannon B; Di Tondo U; Alo PL
Gynecol Oncol; 2004 Jan; 92(1):101-5. PubMed ID: 14751145
[TBL] [Abstract][Full Text] [Related]
34. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Hum Pathol; 2006 Dec; 37(12):1568-76. PubMed ID: 16949911
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma.
Alo PL; Amini M; Piro F; Pizzuti L; Sebastiani V; Botti C; Murari R; Zotti G; Di Tondo U
Anticancer Res; 2007; 27(4B):2523-7. PubMed ID: 17695548
[TBL] [Abstract][Full Text] [Related]
36. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients.
Stein JP; Clark P; Miranda G; Cai J; Groshen S; Skinner DG
J Urol; 2005 Apr; 173(4):1163-8. PubMed ID: 15758728
[TBL] [Abstract][Full Text] [Related]
37. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
38. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
May M; Nitzke T; Helke C; Vogler H; Hoschke B
Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
[TBL] [Abstract][Full Text] [Related]
39. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
